1031289-75-4

Usage

Uses

Used in Organic Synthesis:
N1,N1-DiMethylcyclohexane-1,4-diaMine dihydrochloride is used as a reagent in the preparation of various organic compounds, leveraging its chemical properties and structure to facilitate the synthesis process.
Used in Pharmaceutical Research:
In the pharmaceutical industry, N1,N1-DiMethylcyclohexane-1,4-diaMine dihydrochloride serves as a building block for the synthesis of pharmaceuticals and other fine chemicals, contributing to the development of new drugs and therapeutic agents.

Upstream product

• 1286275-84-0 tert-butyl ((1r,4r)-4-(dimethylamino)cyclohexyl)carbamate 
• 1031289-73-2 tert-butyl (1s,4s)-4-(dimethylamino)cyclohexylcarbamate 

Relevant academic research and scientific papers

COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers.

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS

There is provided compounds of formula (I), wherein Ra, Rb, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or Flt3, and, optionally, a PIM family kinase) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS

The present invention relates to a series of substituted heteroaryl amides of the Formula I, wherein HET, A, X1 -X4, and R1-R12 groups are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.